Tyler R. Simpson

6.1k total citations · 2 hit papers
15 papers, 2.5k citations indexed

About

Tyler R. Simpson is a scholar working on Oncology, Immunology and Biomedical Engineering. According to data from OpenAlex, Tyler R. Simpson has authored 15 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Immunology and 2 papers in Biomedical Engineering. Recurrent topics in Tyler R. Simpson's work include Immune Cell Function and Interaction (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and T-cell and B-cell Immunology (6 papers). Tyler R. Simpson is often cited by papers focused on Immune Cell Function and Interaction (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and T-cell and B-cell Immunology (6 papers). Tyler R. Simpson collaborates with scholars based in United States, United Kingdom and Japan. Tyler R. Simpson's co-authors include James P. Allison, Sergio A. Quezada, Karl S. Peggs, Hideo Yagita∥, Welby Montalvo-Ortiz, Jeffrey V. Ravetch, Jake Y. Henry, Fubin Li, Katharina Bergerhoff and Claire Roddie and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Immunity.

In The Last Decade

Tyler R. Simpson

14 papers receiving 2.5k citations

Hit Papers

Fc-dependent depletion of tumor-infiltrating regulatory T... 2010 2026 2015 2020 2013 2010 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
    2013 1.1k citations Tyler R. Simpson, Fubin Li et al. The Journal of Experimental Medicine profile →
  2. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
    2010 635 citations Sergio A. Quezada, Tyler R. Simpson et al. The Journal of Experimental Medicine profile →

Peers

Tyler R. Simpson
Arantza Azpilikueta Spain
Henry Chiu United States
Willemijn Hobo Netherlands
Junrong Xia United States
Inbal Braunstein United States
Eva Lion Belgium
Madhav V. Dhodapkar United States
Erika Ritter United States
Carsten Linnemann Netherlands
Natalia Aptsiauri Spain
Arantza Azpilikueta Spain
Tyler R. Simpson
Citations per year, relative to Tyler R. Simpson Tyler R. Simpson (= 1×) peers Arantza Azpilikueta

Countries citing papers authored by Tyler R. Simpson

Since Specialization
Citations

This map shows the geographic impact of Tyler R. Simpson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tyler R. Simpson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tyler R. Simpson more than expected).

Fields of papers citing papers by Tyler R. Simpson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tyler R. Simpson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tyler R. Simpson. The network helps show where Tyler R. Simpson may publish in the future.

Co-authorship network of co-authors of Tyler R. Simpson

This figure shows the co-authorship network connecting the top 25 collaborators of Tyler R. Simpson. A scholar is included among the top collaborators of Tyler R. Simpson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tyler R. Simpson. Tyler R. Simpson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Olive, Jacqueline K., et al.. (2025). Point-of-care Ultrasound to Screen for Gastrointestinal Dysfunction: Image Acquisition and Interpretation. Journal of Visualized Experiments.
2.
Arbour, Kathryn C., Ben George, Jason T. Henry, et al.. (2025). BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion ( MTAP -del): Clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007.. Journal of Clinical Oncology. 43(16_suppl). 3011–3011. 1 indexed citations
3.
Simpson, Tyler R. & Feng-Jen Yang. (2022). Some Hands-on Approaches to Fake Political News Detection. 12. 179–188. 1 indexed citations
4.
Simpson, Tyler R. & Christopher Depcik. (2022). Multiple Fuel Injection Strategies for Compression Ignition Engines. Energies. 15(14). 5214–5214. 6 indexed citations
5.
Elpek, Kutlu G., Ellen Duong, Martin Fan, et al.. (2020). ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS ONE. 15(9). e0239595–e0239595. 23 indexed citations
6.
Elpek, Kutlu G., Christopher J. Harvey, Ellen Duong, et al.. (2016). Abstract A059: Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. Cancer Immunology Research. 4(1_Supplement). A059–A059. 1 indexed citations
7.
Harvey, Christopher J., Kutlu G. Elpek, Ellen Duong, et al.. (2015). Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. Journal for ImmunoTherapy of Cancer. 3(S2). 10 indexed citations
8.
Pentcheva‐Hoang, Tsvetelina, Tyler R. Simpson, Welby Montalvo-Ortiz, & James P. Allison. (2014). Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility. Cancer Immunology Research. 2(10). 970–980. 63 indexed citations
9.
Pentcheva‐Hoang, Tsvetelina, et al.. (2014). Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific. 1 indexed citations
10.
Simpson, Tyler R., Fubin Li, Welby Montalvo-Ortiz, et al.. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma. The Journal of Experimental Medicine. 210(9). 1695–1710. 1093 indexed citations breakdown →
11.
Quezada, Sergio A., Karl S. Peggs, Tyler R. Simpson, & James P. Allison. (2011). Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunological Reviews. 241(1). 104–118. 202 indexed citations
12.
Quezada, Sergio A., Tyler R. Simpson, Karl S. Peggs, et al.. (2010). Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. The Journal of Experimental Medicine. 207(3). 637–650. 635 indexed citations breakdown →
13.
Simpson, Tyler R., Sergio A. Quezada, & James P. Allison. (2010). Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Current Opinion in Immunology. 22(3). 326–332. 174 indexed citations
14.
Quezada, Sergio A., Karl S. Peggs, Tyler R. Simpson, et al.. (2008). Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. The Journal of Experimental Medicine. 205(9). 2125–2138. 174 indexed citations
15.
Rivera, Amariliz, Heather L. Van Epps, Tyler R. Simpson, et al.. (2006). Innate Immune Activation and CD4+ T Cell Priming during Respiratory Fungal Infection. Immunity. 25(4). 665–675. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arantza Azpilikueta Breakdown of academic impact, for papers by Henry Chiu Breakdown of academic impact, for papers by Willemijn Hobo Breakdown of academic impact, for papers by Junrong Xia Breakdown of academic impact, for papers by Inbal Braunstein Breakdown of academic impact, for papers by Eva Lion Breakdown of academic impact, for papers by Madhav V. Dhodapkar Breakdown of academic impact, for papers by Erika Ritter Breakdown of academic impact, for papers by Carsten Linnemann Breakdown of academic impact, for papers by Natalia Aptsiauri
Rankless by CCL
2026